Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

goserelin acetate / Generic mfg.

NCT00099086: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Completed

Bicalutamide, Casodex, docetaxel, Taxotere, GnRh analog, Zoladex, goserelin acetate, leuprolide acetate, Lupron, radiotherapy

Medical University of South Carolina

Prostate Cancer

01/11

12/23

NCT02023463: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Active, not recruiting

Enzalutamide, Xtandi, MDV3100, Goserelin acetate, Goserelin, Zoladex, Leuprolide acetate, Leuprorelin, Leuprolide, Radiation therapy, irradiation, radiotherapy, therapy, radiation

Sidney Kimmel Cancer Center at Thomas Jefferson University, Astellas Pharma Inc, Medivation, Inc.

Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer

07/17

01/40

ChiCTR-OIC-16007962: A non-randomized study of preoperative chemotherapy with or without endocrine therapy in hormone receptor positive breast cancer

Recruiting

100

chemotherapy (Epirubicin plus paclitaxel) combined with aromatase inhibitor ± goserelin (according to menopausal status) ;chemotherapy (Epirubicin plus paclitaxel)

Chinese Academy of Medical Sciences & Peking Union Medical College; Chinese Academy of Medical Sciences & Peking Union Medical College, scientific research funds

Breast cancer

NCT02626507: Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

	gedatolisib plus Ibrance in ER+/HER2- metastatic breast cancer
	Apr 2021 - Apr 2021: gedatolisib plus Ibrance in ER+/HER2- metastatic breast cancer

Active, not recruiting

Gedatolisib, Code name PF-05212384, PKI-587, Faslodex, Fulvestrant, Palbociclib, Ibrance, Zoladex, goserelin

Hoffman Oncology, DSCS CRO

Breast Cancer

02/22

03/22

NCT03511196: Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Active, not recruiting

Adaptive Androgen Deprivation Therapy (ADT), GnRH agonist, Abiraterone, Standard of Care, Zytiga, Prednisone, Glucocorticoid

H. Lee Moffitt Cancer Center and Research Institute

Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate

06/22

06/24

NCT03436745: The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Completed

Zolpidem

National Cancer Institute (NCI)

Prostatic Neoplasms

01/24

GO39932, NCT03332797: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Active, not recruiting

181

Europe, US, RoW

GDC-9545, Giredestrant, RO7197597, RG6171, Palbociclib, LHRH Agonist

Genentech, Inc.

Breast Cancer

06/25

NCT05870579: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Recruiting

Europe

[68Ga]Ga-NeoB, gallium neoB, [177Lu]Lu-NeoB, lutetium neoB, Ribociclib, kisqali, Fulvestrant, Goserelin, zoladex

Novartis Pharmaceuticals

Breast Cancer

12/31



	Diseases Companies Products Productz Mechanisms of Action Sites